Is tamoxifen a rational chemoprevention choice?
G. H. Perkins, L. P. Middleton, A. A. Sahin, S. E. Singletary Multidisciplinary Breast Center Cancer Research Group UT M. D. Anderson Cancer Ctr, Houston, TX 1012 Body: Purpose: Tamoxifen is a proven chemopreventive modality that reduces the risk of invasive breast cancer by over 50% in high risk women. LCIS is a known risk factor for the development of breast cancer; however, the use of tamoxifen for prevention in LCIS is based upon data for ER+ receptor status of LCIS associated with invasive cancer. Tamoxifen use in randomized trials has been beneficial for ER+ patients. There is no published literature on hormone receptor status of LCIS not associated with invasive cancer. We therefore examined the receptor status of patients with ALH and LCIS not associated with invasive breast cancer to identify patients that may not benefit from tamoxifen therapy. Methods: Core biopsy material of 50 patients diagnosed with ALH and LCIS between 1999 and 2004 at UTMDACC was examined. Histology was
Related Questions
- I am currently using raloxifene (brand name: Evista) along with tamoxifen for breast cancer chemoprevention. Is raloxifene metabolized in the same way as tamoxifen (using 2D6)?
- Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
- Are there any foods I should avoid while taking Tamoxifen?
